London and Boston (OTE) – Precision oncology leader joins world-class
team as company enters
next phase of translating AI-driven drug discovery into life-changing
medicines.
Isomorphic Labs, the AI-first drug discovery company, has
announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief
Medical Officer. Dr. Wolf will be based in the company’s newly
established Cambridge location, where he will establish a group of
world-class biomedical talent as the company advances its work
translating AI-driven drug discovery into life-changing medicines.
The news follows the company raising $600m in its first external
investment round earlier this year.
As Chief Medical Officer, Dr. Wolf will bring his nearly 20 years
of biopharmaceutical experience to Isomorphic Labs, including
expertise in precision oncology and advancing novel therapeutic
programmes from discovery through to regulatory approval.
“We’re entering a new era for drug discovery in which our next-
generation AI drug design engine can unlock deeper scientific
insights,” said Sir Demis Hassabis, CEO of Isomorphic Labs. “To turn
those insights into real breakthroughs we need to translate them into
medicines that can transform patient lives. Ben’s expertise in
advancing clinical programs from early development through
registration makes him the ideal person to lead our work in this
area. I’m delighted to have him on board!”
Most recently, Dr. Wolf served as Chief Medical Officer at Relay
Therapeutics, leading the company’s clinical trials and advancing
multiple molecules into pivotal testing. Prior to this, he was CMO at
KSQ Therapeutics, where he advanced a CRISPR-based cancer therapeutic
pipeline. In his previous role at Blueprint Medicines, Dr. Wolf
applied his clinical expertise to development of next generation
small molecule kinase inhibitors. He has authored more than 40 peer-
reviewed publications and is an inventor on multiple patents related
to drug discoveries.
“Isomorphic Labs represents the future of drug discovery and
design – one where AI doesn’t just accelerate existing processes but
fundamentally transforms how we approach some of medicine’s greatest
challenges,” said Dr. Wolf. “It’s incredible to see what Isomorphic
Labs’ unified drug design engine is capable of, enabling the team to
cross multiple therapeutic areas and drug modalities, opening up new
avenues for treating diseases. I’m excited to join the team and lead
the work translating breakthrough discoveries into transformational
treatments for patients globally.”
The newly established US presence, in Kendall Square in
Cambridge, Massachusetts, where Dr. Wolf will be based, will serve as
a key operational hub, leveraging the city’s world-renowned
biomedical ecosystem, while working closely with teams in London and
Lausanne.
“Ben’s appointment and our newly established US presence
exemplifies our commitment to assembling a world-class,
interdisciplinary team that combines the best of AI innovation in
drug discovery, with proven drug development expertise,” said Colin
Murdoch, President of Isomorphic Labs. “Our US expansion adds the
additional infrastructure needed as we continue to make progress
towards realising our ambitious mission of solving disease.”
About Dr. Ben Wolf, Chief Medical Officer, Isomorphic Labs
Dr. Wolf brings nearly 20 years of biopharmaceutical experience
to Isomorphic Labs, with particular expertise in precision oncology
and advancing novel therapeutic programs from investigational new
drug applications to regulatory approval. Most recently, Dr. Wolf
served as Chief Medical Officer at Relay Therapeutics, leading the
company’s clinical trials. Prior to this he was CMO at KSQ
Therapeutics, where he advanced a CRISPR-based cancer therapeutic
pipeline. He has also held senior clinical development roles at
Blueprint Medicines, where he led multiple precision medicine
programs for kinase inhibitors to successful registration, including
Ayvakit™ and Gavreto™. His earlier experience includes clinical and
translational roles at Genentech, Amgen, Merrimack Pharmaceuticals,
and ImmunoGen.
Dr. Wolf has authored more than 40 peer-reviewed publications and
is an inventor on multiple patents related to drug discoveries. He
earned his B.S. from Union College and M.D. and Ph.D. in biochemistry
from the University of Virginia, completing medical training in
internal medicine and medical oncology at the University of
California at San Diego.
About Isomorphic Labs
Isomorphic Labs was founded in 2021, with a mission to transform
drug discovery with the power of artificial intelligence, ushering in
a new era of biomedical breakthroughs. Isomorphic Labs is led by AI
pioneer Sir Demis Hassabis, and its founding was built on the Nobel-
winning AI breakthrough, AlphaFold. Isomorphic Labs, together with
Google DeepMind, developed and released AlphaFold 3 in May 2024, a
revolutionary AI model that can predict the structure and
interactions of all of life’s molecules with unprecedented accuracy.
Isomorphic Labs has built a world-leading AI drug design engine
comprising foundational AI models that are capable of working across
multiple therapeutic areas and drug modalities. The company is
continually innovating on model architecture and developing cutting-
edge capabilities to advance drug design. Isomorphic Labs is
headquartered in London and has office locations in Lausanne,
Switzerland and Cambridge, Massachusetts.
Digital press kit: http://www.ots.at/pressemappe/PR179169/aom